1 |
Barcelo M, Alvarez Sanchez A, Garcia Sanchez R, et al.Weight Gain and Somatization are associated with the Onset of Gastroesophageal Reflux Diseases: Results of Two 5-year Follow-up Studies[J]. J Clin Gastroenterol, 2016, 50(3): 202-207.
|
2 |
Hsu CS, Liu TT, Wen SH, et al.Clinical, metabolic, and psychological characteristics in patients with gastroesophageal reflux disease overlap with irritable bowel syndrome[J]. Eur J Gastroenterol Hepatol, 2015, 27(5): 516-522.
|
3 |
Yang XJ, Jiang HM, Hou XH, et al.Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life[J]. World J Gastroenterol, 2015, 21(14): 4302-4309.
|
4 |
Boltin D, Boaz M, Aizic S, et al.Psychological distress is not associated with treatment failure in patients with gastroesophageal reflux disease[J]. J Psychosom Res, 2013, 75(5): 462-466.
|
5 |
Kim SE, Kim N, Oh S, et al.Predictive factors of response to proton pump inhibitors in korean patients with gastroesophageal reflux disease[J]. J Neurogastroenterol Motil, 2015, 21(1): 69-77.
|
6 |
Wang AJ, Wang H, Xu L, et al.Predictors of clinical response of acid suppression in Chinese patients with gastroesophageal reflux disease[J]. Dig Liver Dis, 2013, 45(4): 296-300.
|
7 |
Feng CC, Yan XJ, Chen X, et al.Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats[J]. Pain, 2014, 155(8): 1591-1604.
|
8 |
Yan XJ, Feng CC, Liu Q, et al.Vagal afferents mediate antinociception of estrogen in a rat model of visceral pain: the involvement of intestinal mucosal mast cells and 5-hydroxytryptamine 3 signaling[J]. J Pain, 2014, 15(2): 204-217.
|
9 |
Fass R. Therapeutic options for refractory gastroesophageal reflux disease[J]. J Gastroenterol Hepatol, 2012, 27 Suppl 3: 3-7.
|
10 |
Katz PO, Gerson LB, Vela MF.Guidelines for the diagnosis and management of gastroesophageal reflux disease[J]. Am J Gastroenterol, 2013, 108(3): 308-328.
|
11 |
Nojkov B, Rubenstein JH, Adlis SA, et al.The inuence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal re?ux disease[J]. Aliment Pharmacol Ther, 2008, 27(6): 473-482.
|